CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
CRISPR Therapeutics (CRSP) to present at Citi 2024 Virtual Oncology Leadership Summit, offering a live webcast and replay option for investors.
02/15/2024 - 08:30 AM
ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 1:00 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events . A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com .
Investor Contact: Susan Kim +1-617-307-7503susan.kim@crisprtx.com
Media Contact: Rachel Eides +1-617-315-4493rachel.eides@crisprtx.com
When will CRISPR Therapeutics present at the Citi 2024 Virtual Oncology Leadership Summit?
CRISPR Therapeutics will present on Wednesday, February 21, 2024, at 1:00 p.m. ET.
Where can investors watch the live webcast of the fireside chat?
Investors can watch the live webcast on the 'Events & Presentations' page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
How long will the replay of the webcast be available?
The replay of the webcast will be archived on the Company's website for 14 days following the presentation.
CRSP Rankings
#3655 Ranked by Stock Gains
CRSP Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
Switzerland
City
Zug
About CRSP
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.